The outcome of antibiotic therapy of Clostridium difficile infection (CDI) is dependent upon the intestinal pharmacodynamics of antimicrobial suppression of the pathogen, host immunity, and microbiome resilience, leading to the observed clinical endpoints of resolution of diarrheal illness in a sustained or temporary pattern. Clinical trials comparing metronidazole to vancomycin show relatively small differences in outcome of approximately 10% for resolution of diarrheal illness (73% vs 81%, respectively) and a smaller difference in risk of recurrence (23% vs 21%), which is expressed as a sustained response [1] (clinical cure without reoccurrence of diarrheal illness) of 50% and 60%, respectively [2] . The congruent sustained responses imply that the dynamics of drug-microbe interaction are similar. However, treatment guidelines [3, 4] support the use of vancomycin for more severe disease, a position which implies that metronidazole is not as effective. Additional data on antimicrobial effects on C. difficile and components of the microbiome are needed to attain a clearer appreciation of strength and weaknesses of treatment choices.
During antibiotic treatment of CDI, pathogen, host, and intestinal microbiome interaction can be conceptualized into 3 phases. Initially, in the majority of instances, antimicrobial exposure asymptomatically impairs the microbiome, leading to overgrowth or blooming [5] of toxigenic C. difficile in the lumen of and on the mucosal surface of the colon. Toxin elaboration, toxin-mediated intestinal mucosal injury, and inflammasome activation [6, 7] lead to clinical features of CDI. In addition to the impairment of the normal microbiota and pathogen growth, it is presumed that the onset of diarrhea further depletes the intestinal microbiota.
Antibiotic treatment of CDI constitutes the second phase of host-microbe interaction, a 10-to 14-day interval during which the net effect of selective or broad-spectrum antimicrobial action balances pathogen eradication with further adverse or beneficial effects on the residual normal intestinal microbiota. The third phase, posttreatment, can be conceptualized as a dynamic struggle between the normal microbiota reconstituting itself in both numbers and diversity vs regrowth of the pathogen, presumptively by regermination of persisting spores [8] . Spores of C. difficile have been observed to develop a biofilm state in vitro that may account for the posttreatment reappearance of the pathogen in the majority of patients [9] . Despite persistence of the pathogen, the resilience of the microbiome to reconstitute itself averts recurrence in most patients.
Although most experts are of the opinion that probiotics are unlikely to be effective for secondary prevention of CDI recurrences, probiotics composed of Lactobacillus and Bifidobacterium species might be effective in primary prevention of CDI for patients receiving antibiotic treatments [10] [11] [12] [13] [14] . The beneficial effect of administering probiotics could be affected by persisting endogenous members of these same groups in CDI patients. Information on the baseline presence of these groups of microbes at the time of diagnosis of CDI and during and following treatment would be of interest.
We report here quantitative cultures of C. difficile and normal microbiota during treatment of CDI in patients recruited to recent clinical trials [2, [15] [16] [17] [18] , and extend the findings by way of quantitative polymerase chain reaction (qPCR) testing for the main components of the normal microflora, primarily Bacteroidetes and Clostridium clusters XIVa and IV, represented by Clostridium coccoides and Clostridium leptum probes, respectively. Specific objectives included the numbers of C. difficile present at diagnosis of CDI, the degree of impairment of the normal microbiota using cultivable genera as an index in comparison to fecal samples from a cohort of healthy volunteers, comparison of the patterns of clearance of C. difficile with different therapies, and patterns of recovery of the normal microbiota.
METHODS
Subjects contributing fecal samples were participants in the following studies: phase 2 comparison of 1 g or 2 g of tolevamer 3 times daily for 14 days vs vancomycin 125 mg 4 times daily for 10 days (n = 30) [14] ; phase 2 OPT-80 (later named fidaxomicin) doseranging study [15] with an additional group of vancomycin controls [16] (n = 40); phase 3 comparison of metronidazole 375 mg 4 times daily for 10 days, vancomycin 125 mg 4 times daily for 10 days, or tolevamer 9-g load followed by 3 g 3 times daily for 14 days [2] (Polymer Alternative for CDI Treatment [PACT] 301 trial [n = 56]; PACT 302 trial [n = 5]). Tolevamer treatment was intended to bind C. difficile toxins A and B, thereby neutralizing the pathogenic potential of C. difficile and to allow the normal microbiota to recover, as a competitive means of suppressing the pathogen [17] .
Fecal samples, 5-30 g, were obtained at study entry and at days 4, 10, 14, 21, 28, and 38-42 on a voluntary basis. Quantitative cultures for C. difficile were performed by final dilution 10 −2,4,6 of fresh, refrigerated 4°C-8°C (not frozen) samples within 12 hours of collection on weekdays and within 60 hours of collection on weekends onto cefoxitin cycloserine fructose agar plates. Clostridium difficile cytotoxin B titers were determined using the HeLa cell cytotoxicity assay with toxin neutralization (CCNA) (Techlab, Blackburg, Virginia). Fecal samples were then frozen −80°C in 5-g aliquots in brainheart infusion broth with 20% glycerol for normal microbiota cultures. Quantitative cultures of the normal microbiota were performed on selective and nonselective media as outlined in the Wadsworth KTL Anaerobic Manual [19] , dilution range 10 −3,5,7,9 . Bacteroides species on Bacteroides Bile Esculin media were used as the main index of the reliably cultivable component of the normal microbiota expected to be present in most subjects. A single technologist (J. E.) performed these cultures over a 4-year period. Real-time quantitative measurement of Bacteroidetes and Clostridium clusters XIVa and IV as main measures of the normal microbiota were performed as outlined in Louie et al [20] with modification of DNA extraction using Zymo Research Fungal/Bacterial DNA miniprep instead of Qiagen QIAamp DNA Mini Kit. Tolevamer appeared to inhibit qPCR using DNA processed by the Qiagen kit. Quantifications are reported as log 10 colony-forming units (CFU)/g wet weight fecal sample, or as log 10 16S ribosomal DNA copies/ g wet weight.
Statistical Analysis
The quantitative bacterial counts of C. difficile and calculated CFU per gram of target organism group by real-time qPCR were log transformed, after which changes in each time of collection were compared between groups using Wilcoxon signedrank tests for nonparametric data (GraphPad Prism, GraphPad, San Diego, California). Differences in proportion were evaluated by Fisher exact, Yates correction, 2-sided.
RESULTS
Quantitative cultures of fecal samples obtained from 5 healthy control subjects (Table 1) showed Bacteroides species counts >10 11 /g with at least 4 different species per individual. Enteric gram-negative organisms were in 10 9 /g range and recoverable
clostridial species in the 10 8 /g range.
The results of conventional fecal cultures obtained from 103 subjects with CDI at study entry are summarized in Table 2 . Clostridium difficile was recovered from 98 subjects in mean log 10 -counts ± standard deviation of 6.74 ± 2.0 (range, 2.0-11.3). Bacteroides species counts in samples from subjects with CDI (mean, 10 6.5 ± 3.2 /g) represented a mean 10 −5 reduction compared with samples from healthy controls. A wide variation in range of reduction was observed. Only 3 showed counts in the normal range; one-third showed count reductions of 1-3 log 10, another third by 2-6 log 10 counts, and the remaining one-third showing counts at or below the lower limit of detection (LLOD) (3 log 10 CFU/g). Lactobacillus species and non-C. difficile clostridial species remained cultivable in the majority of subjects, whereas Bifidobacterium species were recovered less frequently.
The results of serial quantitative cultures over a 7-week interval for C. difficile in subjects randomized to metronidazole, vancomycin, or tolevamer [2] are shown in Table 3 and illustrated in Figure 1 . For tolevamer subjects who responded to treatment (n = 14), C. difficile counts remained high throughout the treatment period (P = .39 comparing study entry vs day 14 samples), but gradually declined by day 42 to mean counts below but not different than found for antibiotic recipients (P = .09 comparing combined metronidazole and vancomycin subject samples at day 42 vs tolevamer subject samples). Vancomycin consistently reduced counts of C. difficile to the LLOD by days 10-14 (P = .0001). Counts of C. difficile were generally near the LLOD by day 4 with vancomycin therapy. Metronidazole also significantly reduced mean counts by 10 days of treatment (P = .03). However, in metronidazole subjects, although approximately half of the patients did achieve a reduction to LLOD at day 10 of treatment, the remainder showed persistence in Table 2 . Data are presented as colony-forming units per gram of fecal sample, mean ± standard deviation (No. of subjects). a Tolevamer: 9-g loading dose followed by 3 g 3 times daily for 14 days.
b Vancomycin: 125 mg 4 times daily for 10 days.
c Metronidazole: 375 mg 3 times daily for 10 days.
counts 3.0-7.7 log 10 CFU/g. At the end of treatment, metronidazole counts were observed to be significantly higher than for vancomycin patients (P = .045). For both metronidazole and vancomycin treatments, a rebound in counts in the 1-3 week posttreatment period was observed. Figure 2 shows the effect of metronidazole on C. difficile and normal microbiota components as measured by qPCR. Samples obtained from metronidazole subjects participating in the phase 3 tolevamer study (n = 14) were retested using qPCR for C. difficile, Bacteroidetes, and clostridial clusters XIVa (C. coccoides) and cluster IV (C. leptum) counts. Six additional CDI patients receiving metronidazole as standard therapy also submitted samples to increase the number of subjects. Metronidazole is less efficient at reducing pathogen burden by 10 days of treatment and is associated with a 1.5-3 log 10 reduction in Bacteroidetes counts, but appears to have a lesser effect on Firmicutes. The decrease in Bacteroides species counts was more pronounced in the additional metronidazole subjects (≥3 log 10 /g) who had primary CDI, as compared to the tolevamer study patients for whom recurrence and multiple recurrences were included, resulting from lower study entry counts (Table 1) . Table 4 summarizes the correlation of clinical response to vancomycin or tolevamer treatment of CDI in phase 2 and phase 3 trial subjects using 3 laboratory parameters obtained during the treatment interval of 10-14 days: toxin neutralization by CCNA, reduction of C. difficile counts ≤3 log 10 CFU/g fecal sample, and increase or persistence of Bacteroides species total counts as a microbiome marker. Patients randomized to vancomycin responded to treatment in association with suppression of C. difficile counts and disappearance of toxin in fecal samples, but the majority showed suppression of Bacteroides species. Combining the patients who responded to tolevamer 1, 2, or 3 g (3 times daily) treatment or who did not respond, and hence were removed from tolevamer treatment (and placed on vancomycin, at which point data are censored), response to tolevamer is associated with a statistical trend (P = .07) correlating response with toxin neutralization and in association with persisting or higher Bacteroides species counts (P = .0001). Failure of response appeared to be associated with lack of toxin neutralization, persistent diarrhea, and declining Bacteroides species counts (data not shown). Fecal samples from respondents to tolevamer treatment in the phase 3 trial were retested by qPCR (Figure 3) . Persistence of the main components of the microbiome is observed as well as high counts of C. difficile, reflecting the earlier results obtained by conventional culture.
DISCUSSION
Antimicrobial treatment of CDI continues to evolve with the availability of newer treatments [18] that are designed to be more selective against C. difficile and more sparing of the normal microbiota. However, metronidazole and vancomycin remain as standard treatments recommended by the Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases, and American College of Gastroenterology guidelines [3, 4, 21] , accounting for the Table 1 are displayed using mean log counts ± standard error of the mean to illustrate the dynamics of reduction of Clostridium difficile counts over time. Abbreviations: CFU, colony-forming units; QID, 4 times daily; TID, 3 times daily. Figure 2 . Mean log 10 16S ribosomal DNA (rDNA) ± standard deviation/g feces of normal microbiota components and change in Clostridium difficile counts with metronidazole treatment in 14 Genzyme 301 trial participants plus 6 metronidazole-treated patients as additional subjects. Mean 16S rDNA copies of Bacteroidetes, Clostridium clusters XIVa (Clostridium coccoides) and IV (Clostridium leptum), and C. difficile. Abbreviation: CFU, colony-forming units. majority of treatments. Based on the data presented here, the pharmacodynamic effect of metronidazole on treatment of CDI is different from that of vancomycin. Higher C. difficile counts at end of metronidazole treatment could be associated with a lower response rate and could explain early recurrences. Recurrences appeared earlier following metronidazole treatment in the tolevamer phase 3 trials [2] supporting the possible effect of a higher pathogen load at end of treatment. Whereas in vitro antimicrobial resistance is reported infrequently, low fecal concentrations of metronidazole reported by Bolton and Culshaw [22] toward the end of treatment could account for persistence of C. difficile. A cohort study by Al Nassir [23] reported that patients who did not respond to metronidazole treatment were found to have persistently higher counts of C. difficile and required a change to vancomycin therapy. Since minimum inhibitory concentrations to metronidazole for BI/NAP1/ribotype 027 strains are higher in the 1-2 mg/L range, rather than ≤0.5 mg/L for other strains [24, 25] , patients receiving antimicrobial therapy for CDI need to be closely monitored for response to treatment. The findings in this report support a position that failure of response to metronidazole is linked to pathogen persistence and that early recurrences of CDI following metronidazole therapy may to be due to incomplete suppression of the pathogen in combination with moderate impairment of the host microflora. In contrast, vancomycin markedly and rapidly reduces pathogen counts, but is associated with a more profound effect on the microbiome [16, 20] . Abbreviations: CFU, colony-forming units; CDI, Clostridium difficile infection; NSQ, not sufficient quantity; QID, 4 times daily; TID, 3 times daily.
* P = .07 that C. difficile toxin B neutralization is associated with clinical response.
** P = .0001 that recovery of Bacteroides is associated with clinical response. Figure 3 . Fecal samples retrieved from respondents to tolevamer treatment in the phase 3 clinical trial showed no reduction in normal microbiota component counts, but also show the persistence of Clostridium difficile, similar to the results of conventional cultures. The y-axis shows mean log 10 16S ribosomal DNA (rDNA) ± standard deviation/g feces sample. Subjects received 9 g of tolevamer loading dose followed by 3 g, 3 times daily orally for 14 days. Abbreviation: CFU, colony-forming units. [20] .
Abbreviations: CFU, colony-forming units; SD, standard deviation. a Receiving vancomycin or fidaxomicin for 10 days, followed by 4 weeks of follow-up.
The severity of depletion of the microbiome in CDI patients appears to be highly variable. Based on the quantitative cultures using Bacteroides species as a marker for the status of the microflora, a mean 4-5 log 10 /g reduction is observed, with variance of ±2-3 log 10 /g. The relative importance and individual roles of Bacteroidetes vs members of the Firmicutes in establishing colonization resistance against gut pathogens is not established [21] . Following completion of antibiotic treatment of CDI, most patients show strong resilience by rapid increase of normal flora counts [20] . However, a subject enrolled in one of the studies [16] was observed to have persistently low Bacteroides species counts in the 3-4 log 10 /g range for 6 weeks after treatment and suffered recurrence of CDI one day after completion of study monitoring on day 53. Factors that account for resilience of the normal microbiota are largely unknown at present.
Although tolevamer is not being developed further as a treatment for CDI, the observation that neutralization of toxin appears to be associated with clinical response provides a degree of vindication of the original strategy. However, the failure to attain a sufficiently high response rate highlights the importance of killing the pathogen as a therapeutic objective. The qPCR verification that Bacteroidetes and Firmicutes are not measurably impacted in total numbers, combined with a low 6% recurrence rate in responders to tolevamer [2] , does support the original contention that toxin neutralization is a valid treatment pathway. Prior treatment to reduce pathogen counts followed by toxin binding may be a consideration.
A consensus is emerging that probiotics may be of benefit in preventing CDI [10] . Normal healthy control stools contained relatively high counts of lactobacilli [20] . At the time of diagnosis of CDI, most subjects in this report are positive for Lactobacillus species in counts that are similar to those found in control fecal samples. Lactobacillus and Bifidobacterium counts were unaffected by vancomycin or fidaxomicin treatment of CDI, and counts remained stably high in the posttreatment period (Table 5 ) [20] and were similar to results of samples obtained from normal volunteers. Bifidobacteria have also been found to persist in a human gut model treated with metronidazole [26] , suggesting a role in preserving microbiota. It is hypothesized that the persistence of a microbiome component prior to, during, and after CDI represents a positive host defense attribute in a nonspecific manner. Supplementation or augmentation of these microbial groups could potentially improve host defenses. If large-scale preventive probiotic studies confirm a biological benefit of reduced risk of C. difficile infection, microbiologic and metabolomic studies of the intestinal contents to characterize mechanisms of disease prevention are in order.
In summary, for the treatment of C. difficile infection, metronidazole and vancomycin show different pharmacodynamic properties in the intestinal milieu, leading to differences in clinical response and in pathways to recurrence of CDI. An understanding of the interaction between antimicrobial agents, the pathogen, and the normal protective microbiota is essential for the provision of optimal care to patients affected by CDI.
Notes

